All In Biotech

Drug Trial Radar · NCT03150810

Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Dec 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

139

Actual

Start

Jun 28, 2017

Primary completion

May 4, 2023

Study completion May 4, 2023

Sponsor

Lead sponsor
BeiGeneBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
Collaborators
Myriad Genetics, Inc.
First posted
May 12, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study was to determine the safety and tolerability of pamiparib, the maximum tolerated dose (MTD) or maximum administered dose (MAD) for pamiparib combined with TMZ, to select the recommended Phase 2 dose (RP2D) and schedule of pamiparib in combination with TMZ, and to determine the antitumor activity of pamiparib in combination with TMZ.

Conditions

  • Locally Advanced or Metastatic Solid Tumors

Interventions

  • PamiparibDrug

    Administered by mouth as a capsule twice daily

  • TemozolomideDrug

    TMZ at various doses administered by mouth as a capsule once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: From first dose of study drug(s) to 28 days post-dose (up to approximately 1 year and 6 months)
  2. Number of Participants Experiencing Adverse Events (AEs)Time frame: From the first dose of study drug(s) to 30 days after the last dose; up to approximately 5 years and 10 months
  3. Objective Response Rate (ORR)Time frame: Up to approximately 5 years and 10 months

Locations

22 sites in 4 countries. Site status is shown where the registry gives one.

  • Start Midwest

    Grand Rapids, Michigan

  • Washington University in St Louis

    St Louis, Missouri

  • Mount Sinai Prime

    New York, New York

  • Montefiore Medical Park At Eastchester Einstein Campus

    The Bronx, New York

  • Sarah Cannon Cancer Center

    Nashville, Tennessee

  • Texas Oncology (Loop) Usor

    Dallas, Texas

  • The University of Texas Md Anderson Cancer Center

    Houston, Texas

  • Chris Obrien Lifehouse

    Camperdown, New South Wales, Australia

  • Saint Vincents Hospital Sydney

    Darlinghurst, New South Wales, Australia

  • Icon Cancer Centre South Brisbane

    South Brisbane, Queensland, Australia

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, Australia

  • Hospital Universitario Vall Dhebron

    Barcelona, Spain

  • Ico H Duran I Reynals

    Barcelona, Spain

  • Hospital Universitario Ramon Y Cajal

    Madrid, Spain

  • Start Madrid Fundacion Jimenez Diaz

    Madrid, Spain

  • Centro Integral Oncologico Clara Campal

    Madrid, Spain

  • Hospital Universitario Virgen de La Macarena

    Seville, Spain

  • Hospital Clinico Universitario de Valencia

    Valencia, Spain

  • Beatson West of Scotland Cancer Centre

    Glasgow, United Kingdom

  • Northern Centre For Cancer Care

    High Heaton, United Kingdom

  • University College Hospital

    London, United Kingdom

  • Sarah Cannon Research Institute Uk

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.